EU watchdogs reverse course on Fampyra

Reversing an earlier decision, European regulators have recommended approving Acorda Therapeutics' drug Fampyra, which is designed to improve the walking ability of patients with multiple sclerosis. If approved, it will be marketed in Europe by Biogen Idec. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.